Atovaquone
Atovaquone, Malarone, Mepron (atovaquone) is a small molecule pharmaceutical. Atovaquone was first approved as Mepron on 1992-11-25. It is used to treat cerebral toxoplasmosis, malaria, and pneumocystis pneumonia in the USA. It is known to target Cytochrome b.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| respiratory tract diseases | D012140 |
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Atovaquone, Mepron (discontinued: Mepron)
CombinationsAtovaquone proguanil, Malarone
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atovaquone | ANDA | 2024-10-04 |
| atovaquone and proguanil hcl | NDA authorized generic | 2023-10-23 |
| atovaquone and proguanil hydrochloride | ANDA | 2024-10-10 |
| atovaquone and proguanil hydrochloride atovaquone and proguanil hydrochloride pediatric | ANDA | 2019-12-31 |
| atovaquone oral suspension | ANDA | 2024-02-15 |
| malarone | New Drug Application | 2023-11-14 |
| mepron | New Drug Application | 2023-07-20 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01A: Agents against amoebiasis and other protozoal diseases
— P01AX: Other agents against amoebiasis and other protozoal diseases in atc
— P01AX06: Atovaquone
— P01B: Antimalarials
— P01BB: Biguanide antimalarials
— P01BB51: Proguanil and atovaquone
HCPCS
No data
Clinical
Clinical Trials
58 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 10 | 8 | 2 | 7 | 10 | 33 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 3 | 3 | 2 | 3 | 7 | 15 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 4 | 2 | 1 | 3 | 11 |
| Pneumonia | D011014 | EFO_0003106 | — | 1 | 3 | 2 | 1 | 3 | 10 |
| Pneumocystis pneumonia | D011020 | EFO_0007448 | B59 | 1 | 3 | 2 | 1 | 2 | 9 |
| Rabies | D011818 | — | A82 | — | — | — | 1 | — | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | — | 1 | — | 1 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 2 | 1 | — | 2 | 5 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | 1 | — | 1 | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Communicable diseases | D003141 | — | — | — | 2 | — | — | 2 | 4 |
| Toxoplasmosis | D014123 | EFO_0007517 | B58 | 1 | 1 | — | — | 1 | 3 |
| Covid-19 | D000086382 | — | — | — | 2 | — | — | 1 | 3 |
| Cerebral toxoplasmosis | D016781 | EFO_0007200 | B58.2 | — | 1 | — | — | 1 | 2 |
| Encephalitis | D004660 | HP_0002383 | — | — | 1 | — | — | 1 | 2 |
| Bacterial infections | D001424 | — | A49 | — | 1 | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | 1 | — | — | — | 1 |
| Serous cystadenocarcinoma | D018284 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | — | — | — | — | 2 |
| Hiv | D006678 | — | — | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | — | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Atovaquone |
| INN | atovaquone |
| Description | Atovaquone is a naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position. It has a role as an antimalarial, an antifungal agent, an EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor, an EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor and an EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor. It is a member of monochlorobenzenes and a hydroxy-1,4-naphthoquinone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 95233-18-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1450 |
| ChEBI ID | 575568 |
| PubChem CID | 74989 |
| DrugBank | DB01117 |
| UNII ID | Y883P1Z2LT (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
MT-CYB
MT-CYB
Organism
Plasmodium falciparum
Gene name
MT-CYB
Gene synonyms
COB, CYTB, MTCYB
NCBI Gene ID
—
Protein name
Cytochrome b
Protein synonyms
Complex III subunit 3, Complex III subunit III, Cytochrome b-c1 complex subunit 3, Ubiquinol-cytochrome-c reductase complex cytochrome b subunit
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Atovaquone – Amneal Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Atovaquone
+
Proguanil
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,101 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,248 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use